Mitigating the Risk of Skeletal Events in Metastatic Renal Cell Carcinoma
Year: 2025
Type: article
Abstract: Bone metastases affect approximately one-third of patients with metastatic renal cell carcinoma (mRCC) and contribute to substantial skeletal complications and shorter survival. Management of these metastases requires a multidisciplinary approach combining systemic therapies, localized treatments, and supportive care. Immune checkpoint inhibitor (ICI)-based combinations, especially doublets comprising an ICI and a VEGF-targeted tyrosine kinase inhibitor, have shown significant efficacy in mRCC with bone involvement. Bone-modifying agents such as zoledronic acid and denosumab help in mitigating symptomatic skeletal-related events and enhance bone integrity, although the unique bone pathology of RCC may limit their effectiveness. Local therapies, such as surgery and stereotactic body radiotherapy, play a pivotal role in providing symptom relief and controlling localized disease, particularly in oligometastatic cases. A personalized, patient-centered strategy is essential in minimizing systemic therapy disruptions, addressing skeletal morbidity, and improving clinical outcomes. PATIENT SUMMARY: Bone metastases in patients with kidney cancer can cause severe complications such as pain, fractures, and other serious issues, reducing quality of life and survival. Treatment involves a combination of therapies, including medications, targeted radiation, surgery, and immunotherapy, tailored to each patient to manage symptoms and improve outcomes.
Source: European Urology Focus
Authors: Yu-Wei Chen, Rana R. McKay
Institutions: University of California San Diego, Moores Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,800
OpenAlex ID: W4409813865